Evidence map›Paper›PMID 40093309›Full record

ArticleAmerican heart journal plus : cardiology research and practice2025

Myocardial biomarkers in coronary microvascular dysfunction: Response to ranolazine.

Katherine E Hampilos, Anum Asif, Puja K Mehta, Daniel S Berman, Galen Cook-Wiens, Michael D Nelson, Carl J Pepine, C Noel Bairey Merz, Janet Wei

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American heart journal plus : cardiology research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01342029 (Treatment With Ranolazine in Microvascular Coronary Dysfunction), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01342029 nacompletednot on this map

Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia

TypeinterventionalSponsorCedars-Sinai Medical CenterRan2011 to 2016Enrolled142ConditionsMicrovascular Coronary Dysfunction (MCD)ArmsRanolazine, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Katherine E HampilosBarbra Streisand Women's Heart Center, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, USA.
Anum AsifDivision of Cardiology, University of Texas San Antonio, San Antonio, TX, USA.
Puja K MehtaDivision of Cardiology, Emory University School of Medicine, Atlanta, GA, USA.
Daniel S BermanS. Mark Taper Foundation Imaging Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Galen Cook-WiensBiostatistics and Bioinformatics Research Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Michael D NelsonDepartment of Kinesiology, University of Texas in Arlington, Arlington, TX, USA.
Carl J PepineDivision of Cardiology, University of Florida, Gainesville, FL, USA.
C Noel Bairey MerzBarbra Streisand Women's Heart Center, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, USA.
Janet WeiBarbra Streisand Women's Heart Center, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, USA.

Funding

ZONA-FREE HAMSTER OVA ASSAY AS AN INDICATOR OF MALE FERTILITYM01RR000425 · NCRR · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI WANG, CHRISTINA C. · 1985 to 2011
$74.2M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
Using social networks to map and evaluate team science across CTSA hubsUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2015 to 2024
$37.2M
UCLA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR033176 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2011 to 2011
$15.5M
Quantitative Prediction of Disease and Outcomes from Next Generation SPECT and CTR01HL089765 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI SLOMKA, PIOTR J · 2007 to 2021
$6.1M
Women's Ischemia Syndrome Evaluation (WISE) Coronary Vascular DysfunctionR01HL090957 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI BAIREY MERZ, CATHLEEN NOEL, PEPINE, CARL J · 2008 to 2013
$3.5M
Advanced 3T for Structural and Functional Imaging at University of FloridaS10OD021726 · OD · UNIVERSITY OF FLORIDA · PI LONG, JOANNA R · 2017 to 2017
$2.0M
ISCHEMIC HEART DISEASE IN WOMEN--CLINICAL CENTERN01HV068163 · HV · UNIVERSITY OF FLORIDA · PI PEPINE, CARL J · 1996 to 2001
$386k
ISCHEMIC HEART DISEASE IN WOMEN-CLINICAL CENTERN01HV068161 · HV · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ROGERS, WILLIAM J · 1996 to 2000
$245k
EVAL OF ISCHEMIC HEART DISEASE IN WOMEN-CLINICAL CTRN01HV068164 · HV · ALLEGHENY-SINGER RESEARCH INSTITUTE · PI REICHEK, NATHANIEL · 1996 to 2001
–
EVAL OF ISCHEMIC HEART DISEASE IN WOMEN-CLINICAL CTR-N01HV68162-268068162N01HV068162 · HV · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 1996 to 2005
–
NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1 TR001427NCRR NIH HHS M01 RR000425NCRR NIH HHS UL1 RR033176NHLBI NIH HHS N01 HV068161NHLBI NIH HHS N01 HV068162NHLBI NIH HHS N01 HV068163NHLBI NIH HHS N01 HV068164NHLBI NIH HHS R01 HL089765NHLBI NIH HHS R01 HL090957NIH HHS S10 OD021726
6 · The paper itself

Abstract

Introduction: Patients with coronary microvascular dysfunction (CMD) are at increased risk of developing heart failure with preserved ejection fraction (HFpEF). We hypothesized that higher myocardial biomarkers (ultra-high sensitivity cardiac troponin I [u-hs-TnI]) and ventricular dysfunction (N-terminal pro-BNP [NT-proBNP]) would be related to greater ischemia improvement on the late sodium channel inhibitor ranolazine. Methods: We analyzed CMD participants with baseline myocardial biomarkers randomized to ranolazine or placebo (RWISE trial: NCT01342029). Ischemia response was change in global myocardial perfusion reserve index (∆MPRI) or Seattle Angina Questionnaire (∆SAQ). Results: Among 64 randomized participants with u-hs-TnI and 40 with NT-proBNP, higher u-hs-TnI related to improved ∆MPRI ( Conclusions: These findings suggest that higher u-hs-TnI signals greater ischemia improvement on ranolazine. Further studies evaluating ischemia therapies in CMD are needed to develop potential HFpEF prevention targets.

Indexed as

Coronary microvascular dysfunctionIschemia and no obstructive coronary artery diseaseMyocardial perfusion reserve indexN-terminal pro-BNPRanolazineUltra-high sensitivity cardiac troponin IWomen

Identifiers

PMID40093309
PMCPMC11910371

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.